Crake T, Mulcahy D, Wright C, Fox K
National Heart Hospital, London, U.K.
Eur Heart J. 1988 Nov;9(11):1200-5. doi: 10.1093/oxfordjournals.eurheartj.a062430.
Labetalol, a combined alpha- and beta-receptor antagonist, was compared with nifedipine in a placebo-controlled, randomized double-blind cross over study (four week treatment periods) of 11 normotensive patients with stable exertional angina pectoris. Standard recommended doses of both drugs (labetalol 200-400 mg twice daily, nifedipine 10-20 mg three times daily) were used. Angina frequency was similar during the placebo washout period and treatment with the two drugs. The duration of treadmill exercise to angina, ischaemia (greater than 1 mm ST segment depression), and end of exercise was increased by both labetalol and nifedipine when compared with placebo, but there was no difference between the two drugs. Ambulatory ST segment monitoring demonstrated that the frequency, duration and magnitude of ST segment depression, whether painful or silent, were unaffected by either drug. Labetalol is an effective agent in improving exercise tolerance in normotensive patients with stable exertional angina pectoris, with an efficacy similar to that of nifedipine.
拉贝洛尔是一种α和β受体联合拮抗剂，在一项安慰剂对照、随机双盲交叉研究（为期四周的治疗期）中，将其与硝苯地平对11名患有稳定劳力性心绞痛的血压正常患者进行了比较。两种药物均使用标准推荐剂量（拉贝洛尔每日两次，每次200 - 400毫克；硝苯地平每日三次，每次10 - 20毫克）。在安慰剂洗脱期以及两种药物治疗期间，心绞痛发作频率相似。与安慰剂相比，拉贝洛尔和硝苯地平均使出现心绞痛、缺血（ST段压低超过1毫米）以及运动结束时的跑步机运动持续时间增加，但两种药物之间无差异。动态ST段监测表明，ST段压低的频率、持续时间和幅度，无论是否伴有疼痛，均不受两种药物的影响。拉贝洛尔是改善患有稳定劳力性心绞痛的血压正常患者运动耐量的有效药物，其疗效与硝苯地平相似。
